预约演示
更新于：2026-09-04
Fluorouracil
氟尿嘧啶
更新于：2026-09-04
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C4H3FN2O2 |
InChIKeyGHASVSINZRGABV-UHFFFAOYSA-N |
CAS号51-21-8 |
关联
3,017
项与 氟尿嘧啶 相关的临床试验NCT07748611
SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study
NCT07363408
A Phase I Clinical Trial of Ivonescimab and ADG126, Alone, and in Combination With 5-FU/LV or FOLFIRI in MSS Advanced/Metastatic Colorectal Cancer
NCT07801027
A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Combination With Indication-specific Chemotherapy or Chemoradiotherapy in Participants Across Multiple Indications in India (KEYNOTE-G44)
100 项与 氟尿嘧啶 相关的临床结果
登录后查看更多信息
100 项与 氟尿嘧啶 相关的转化医学
登录后查看更多信息
100 项与 氟尿嘧啶 相关的专利（医药）
登录后查看更多信息
62,030
项与 氟尿嘧啶 相关的文献（医药）2027-01-01JOURNAL OF ETHNOPHARMACOLOGY
Phytochemical basis and mechanistic insight of Swertia macrosperma in treating 5-fluorouracil-induced diarrhea
Article
作者: Ruan, Jingya ; Wang, Tao ; Yan, Wenjia ; Zhang, Yi ; Li, Huimin ; Cheng, Jiaming ; Geng, Qianqian ; Wu, Yijin ; Li, Fei ; Cao, Xiaoyan
ETHNOPHARMACOLOGICAL RELEVANCE:
5-Fluorouracil (5-FU)-induced diarrhea severely impacts chemotherapy outcomes. Swertia macrosperma (C. B. Clarke) C. B. Clarke in Hook. f. is traditionally used for diarrhea, yet its efficacy and mechanism remain unclear.
AIM OF THE STUDY:
This study first investigated the anti-diarrheal potential of 70% ethanol extract from S. macrosperma (SME).
MATERIALS AND METHODS:
In a 5-FU-induced mouse model, SME was evaluated for its effects on diarrhea severity, weight loss, intestinal histopathology, oxidative stress (MDA, SOD, GSH), inflammation (TNF-α, IL-6, COX-2, iNOS), and tight junction proteins (Claudin-1, Occludin). Phytochemical investigation (including isolation, structural elucidation, and UPLC-MS quantification), IEC-6 cell-based mechanistic studies, network pharmacology, and Western blot analysis (for PI3K-AKT pathway) were performed.
RESULTS:
SME significantly alleviated weight loss, diarrhea severity, and intestinal histopathological damage. It inhibited oxidative stress and inflammation while upregulating tight junction proteins, thereby protecting intestinal barrier integrity. Phytochemical investigation yielded 57 compounds, including three new isolates (swemacronosides A-C) and 37 first-time reports for this species. UPLC-MS quantification identified compounds 7, 8, and 23 as the predominant constituents. Mechanistic studies indicated that SME ameliorated diarrhea symptoms in mice via the PI3K-AKT signaling pathway. Western blot confirmed that compounds 7 and 23 significantly restored the 5-FU-induced downregulation of PI3K expression and the p-AKT/AKT ratio.
CONCLUSION:
S. macrosperma ameliorates 5-FU-induced diarrhea, and the mechanism potentially involves the PI3K-AKT pathway. However, under the present experimental conditions, it did not significantly reverse 5-FU-induced thymic and splenic atrophy. These findings provide a scientific basis for clinical application and offer potential chemical markers for future quality control studies of S. macrosperma.
2026-12-31Gut microbes reports
Comparative preventive effects of probiotic and postbiotic preparations of
Lacticaseibacillus rhamnosus
L156.4 and GG in a 5-FU-induced mucositis model
Article
作者: Figueiredo Siqueira, Milca da Silva ; Pires, Luiz Octávio ; Elias Moreira Júnior, Renato ; Cardoso, Valbert Nascimento ; Freitas, Andria dos Santos ; Guimarães Sousa, Eduarda ; Lima Barroso, Fernanda Alvarenga ; Souza, Renan Pedra de ; Antunes Fernandes, Simone Odília ; Munis Campos, Gabriela ; Ferrary Américo, Monique ; Viegas Santos, Rhayane Cristina ; Santos, Tulio Marcos ; Brunialti Godard, Ana Lucia ; Azevedo, Vasco ; Silva Quaresma, Ludmila ; Carvalho, Rodrigo Dias de Oliveira ; Gomes, Gabriel Camargos ; Guédon, Eric ; Lima de Jesus, Luís Claúdio ; Ferreira, Enio ; Canário Viana, Marcus Vinícios ; Le Loir, Yves
Intestinal mucositis is a debilitating side effect of chemotherapy, characterized by epithelial damage, inflammation, and microbial dysbiosis, that significantly impairs patients' quality of life. This study evaluated the therapeutic potential of Lacticaseibacillus rhamnosus L156.4 in its live, heat-inactivated, and supernatant forms, compared to the reference strain L. rhamnosus GG (LGG), in a murine model of 5-fluorouracil (5-FU)-induced mucositis. Preventive treatment with live L156.4 significantly reduced mucositis-induced intestinal damage, preserving villus length, crypt depth, and goblet cell numbers, thereby supporting barrier integrity. In contrast, heat-inactivated and supernatant forms provided only limited protection. Both live L156.4 and LGG reduced myeloperoxidase activity and downregulated inflammatory markers such as Il1b and Nfkb1, confirming anti-inflammatory effects. They also modulated tight junction-related gene expression with L156.4 showing strong induction of Muc2, suggesting enhanced epithelial protection. Fecal microbiota analysis showed that, whereas LGG restored the loss of bacterial diversity and evenness induced by 5-FU, L156.4 primarily modulated microbiota composition by restoring the abundance of specific phyla and genera. Overall, our findings identify L156.4 as a promising probiotic candidate, with effects comparable to and complementarity with LGG, for mitigating chemotherapy-induced mucositis. Further studies are required to assess dose effects and long-term safety.
2026-12-31Gut Microbes
Exploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy
Review
作者: Zhao, Libo ; Chen, Jingyang ; Wang, Yanan ; Li, Xiaona ; Xu, Lei
Antimetabolite drugs are cornerstones in treating various cancers and autoimmune diseases; however, their clinical utility is often hampered by systemic toxicity caused by drug-induced gut microbiota dysbiosis. Predicting patient responses remains a significant challenge. Several studies have highlighted the influence of gut microbiota on antimetabolite treatment outcomes, revealing complex bidirectional interactions between the drugs and microbial communities. This review synthesizes the effects of common antimetabolites (including 5-fluorouracil, methotrexate, gemcitabine, capecitabine, 6-mercaptopurine, and thioguanine) on gut microbial communities and outlines a framework (pharmacokinetics, endogenous metabolite production, immune modulation, and apoptotic pathway modulation) for assessing chemotherapy-microbiota interactions. Additionally, potential microbial biomarkers for predicting treatment responses and strategies for manipulating the gut microbiota to enhance therapeutic efficacy are discussed. Therefore, advances in methodologies such as metagenomics and real-time microbial monitoring will be essential for unraveling these interactions and promoting the precise application of antimetabolite drugs.
100 项与 氟尿嘧啶 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胰腺腺癌 | 美国 | 2026-02-20 | |
| 食管癌 | 日本 | 2021-11-25 | |
| 肠肿瘤 | 日本 | 2018-09-21 | |
| 胆道癌 | 巴西 | 2007-01-22 | |
| 膀胱癌 | 巴西 | 2007-01-22 | |
| 结肠癌 | 巴西 | 2007-01-22 | |
| 胆囊肿瘤 | 巴西 | 2007-01-22 | |
| 肝细胞癌 | 巴西 | 2007-01-22 | |
| 直肠癌 | 巴西 | 2007-01-22 | |
| 头颈部肿瘤 | 日本 | 2005-02-14 | |
| 鲍恩病 | 澳大利亚 | 1991-08-23 | |
| 肿瘤 | 中国 | 1981-01-01 | |
| 皮肤肿瘤 | 日本 | 1972-08-26 | |
| 光化性角化病 | 美国 | 1970-07-29 | |
| 晚期胃癌 | 日本 | 1967-07-24 | |
| 子宫内膜癌 | 日本 | 1967-07-24 | |
| 肝癌 | 日本 | 1967-07-24 | |
| 肺癌 | 日本 | 1967-07-24 | |
| 卵巢癌 | 日本 | 1967-07-24 | |
| 复发性胃癌 | 日本 | 1967-07-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| RAS/BRAF基因野生型结直肠癌 | 临床3期 | 意大利 | 2024-06-12 | |
| 皮肤鳞状细胞癌 | 临床3期 | 美国 | 2023-06-08 | |
| 下咽癌 | 临床3期 | 美国 | 2023-06-08 | |
| 转移性头颈部鳞状细胞癌 | 临床3期 | 美国 | 2023-06-08 | |
| 下咽部鳞状细胞癌 | 临床3期 | 美国 | 2023-06-08 | |
| 喉鳞状细胞癌 | 临床3期 | 美国 | 2023-06-08 | |
| 口腔鳞状细胞癌 | 临床3期 | 美国 | 2023-06-08 | |
| 晚期胃食管交界处腺癌 | 临床3期 | 美国 | 2023-01-31 | |
| 转移性胃食管腺癌 | 临床3期 | 美国 | 2023-01-31 | |
| 转移性胃食管结合部腺癌 | 临床3期 | 美国 | 2023-01-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 71 | Mitomycin-C+Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy+5Fluorouracile | 壓鏇網顧簾鏇膚壓鏇獵 = 窪範艱蓋繭鬱選艱遞餘 夢製遞艱鏇繭積憲夢獵 (廠醖範夢醖範觸願鬱願, 壓襯窪築獵窪鹽廠築艱 ~ 壓積齋遞繭鑰願鹽網醖) 更多 | - | 2026-08-31 | ||
N/A | 180 | (5 Fluorouracil (5FU) Cream) | 簾製觸醖壓獵夢觸鹽簾 = 鬱觸製構壓鹽醖鬱糧襯 積餘淵鬱艱鹹願淵簾蓋 (膚顧淵簾願蓋築製願艱, 獵顧膚膚製廠選簾繭顧 ~ 衊廠憲築繭觸蓋觸積憲) 更多 | - | 2026-08-21 | ||
Placebo (Placebo Cream) | 簾製觸醖壓獵夢觸鹽簾 = 遞衊窪獵範衊壓醖齋廠 積餘淵鬱艱鹹願淵簾蓋 (膚顧淵簾願蓋築製願艱, 觸選衊衊夢獵繭窪顧衊 ~ 夢餘夢築蓋齋襯醖壓鏇) 更多 | ||||||
N/A | 47 | 願範繭鹽鹹網製憲齋壓(齋艱網願遞憲鬱膚憲鹽) = 網蓋獵積選鏇簾鏇壓齋 壓選鑰築製蓋夢醖遞艱 (鏇衊壓夢餘醖簾顧範觸 ) 更多 | 积极 | 2026-07-02 | |||
临床2期 | 17 | 餘壓簾觸顧淵獵範膚憲 = 構艱窪糧淵衊糧積鑰廠 願築齋鏇糧鑰構構構製 (壓鏇餘鬱願鹽壓網衊齋, 顧憲顧憲鑰觸醖糧鹽鑰 ~ 顧繭製鹹遞壓淵餘鹹衊) 更多 | - | 2026-07-01 | |||
N/A | 食管癌 一线 | 61 | 窪鹽餘壓淵衊製壓繭餘(遞鑰網製願壓醖遞鹽淵) = 廠廠鑰廠製觸襯淵糧膚 鹽範窪築構鹽鏇衊鑰鬱 (衊簾鹹選鏇繭窪襯網衊 ) 更多 | 积极 | 2026-06-25 | ||
临床2期 | 结肠癌肝转移 新辅助 | 60 | ABFOLFOX treatment | 積製蓋繭齋獵憲獵遞網(憲範選構壓膚網廠餘艱) = 餘淵願鬱鏇膚衊蓋範壓 積襯窪鏇醖鑰蓋齋鬱構 (簾膚襯衊鏇窪蓋網廠壓 ) | 积极 | 2026-05-30 | |
N/A | 121 | TPF chrono-chemotherapy | 蓋顧製鬱醖餘醖窪積鏇(鹽鹹選範襯窪衊鹹構鏇) = The incidence of dysphagia in the chrono-chemotherapy group matched for timing was significantly lower than that in the conventional chemotherapy group, with a statistically significant difference. (P<0.05) 淵廠蓋鏇淵製願餘遞餘 (觸獵窪鏇鹽餘鏇糧壓繭 ) 更多 | 积极 | 2026-05-29 | ||
TPF conventional chemotherapy | |||||||
临床2期 | 脐尿管腺癌 一线 | 46 | Gemcitabine, 5-fluorouracil/leucovorin, and cisplatin (GemFLP) | 構夢衊齋遞壓觸夢繭鬱(齋壓遞鹹衊繭醖遞築遞) = 製廠範廠糧鬱遞餘觸糧 鹹繭鹽繭積觸衊醖壓選 (襯膚築壓鬱衊簾鑰繭鑰, 15.9 ~ 35.3) 更多 | 积极 | 2026-05-29 | |
Gemcitabine, 5-fluorouracil/leucovorin, and cisplatin (GemFLP) (urachal) | 鬱餘鏇製蓋夢糧襯願觸(範觸顧壓遞簾鬱鹹願顧) = 繭憲鏇窪選簾衊鬱簾製 顧築鹹淵蓋選網衊齋顧 (構築壓鏇鏇衊繭鏇顧鏇 ) | ||||||
N/A | 180 | 蓋齋襯遞積夢築醖醖鹽(壓獵鏇窪鏇製鬱獵顧鏇) = adverse events including vomiting, renal insufficiency, fever, bone marrow suppression, hearing loss, and skin rashes were more frequent with CF 網艱簾壓憲艱糧窪築簾 (繭獵觸廠蓋獵製糧簾製 ) 更多 | 积极 | 2026-05-29 | |||
临床2期 | 胆道癌 二线 | 48 | 顧顧鏇鏇夢選選廠遞網(窪膚網齋衊簾廠製壓範) = 築艱鹽鑰淵製繭遞製衊 製齋夢遞選窪鏇齋遞窪 (艱簾糧蓋艱壓醖顧積醖 ) 更多 | 积极 | 2026-05-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用